1xbet모바일., Ltd.
Pharmaceuticals
September 25, 2018
1xbet모바일
-
Busulfex is used around the world as a pretreatment prior to hematopoietic stem cell transplantation in patients with hematologic cancers
-
The approval in Japan reflects the once-daily usage pattern 1xbet모바일 Busulfex in adults in other countries
-
The addition of a once-daily dosage regimen is expected to reduce the burdens and risks 1xbet모바일 patients and medical staff
1xbet모바일., Ltd. today announces it has received regulatory approval for a once-daily form of Busulfex®Injection 60 mg (generic name is busulfan). Busulfex is a conditioning regimen administered via intravenous drip to patients prior to undergoing hematopoietic stem cell transplantation.
Latest Pharmaceutical Business related News Releases